186 related articles for article (PubMed ID: 38553074)
21. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T.
Akinola IM; Cusatis R; Pasquini MC; Shaw BE; Bollu V; Dalal A; Tesfaye M; Flynn KE
Transplant Cell Ther; 2023 Apr; 29(4):254.e1-254.e9. PubMed ID: 36634738
[TBL] [Abstract][Full Text] [Related]
22. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
23. eHealth System for Collecting and Utilizing Patient Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care) Among Cancer Patients: Mixed Methods Approach to Evaluate Feasibility and Acceptability.
Girgis A; Durcinoska I; Levesque JV; Gerges M; Sandell T; Arnold A; Delaney GP;
J Med Internet Res; 2017 Oct; 19(10):e330. PubMed ID: 28970188
[TBL] [Abstract][Full Text] [Related]
24. Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study.
Dempsey K; Saw R; Bartula I; Lo S; Lawn C; Pennington T; Spillane A; Boyle F; Dong S; Dieng M; Milne D; Seaman L; Saks D; Lai-Kwon J; Thompson JR; Morton R
BMJ Open; 2022 Dec; 12(12):e066852. PubMed ID: 36600423
[TBL] [Abstract][Full Text] [Related]
25. Developing a real-time electronic symptom monitoring system for patients after discharge following cancer-related surgery.
Avery KNL; Richards HS; Portal A; Reed T; Harding R; Carter R; Bamforth L; Absolom K; O'Connell Francischetto E; Velikova G; Blazeby JM
BMC Cancer; 2019 May; 19(1):463. PubMed ID: 31101017
[TBL] [Abstract][Full Text] [Related]
26. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
27. Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.
Martino M; Macheda S; Aguglia U; Arcudi L; Pucci G; Martino B; Altomonte M; Rossetti AM; Cusumano G; Russo L; Imbalzano L; Stelitano C; Alati C; Germano' J; Labate D; Amalfi V; Florenzano MT; Morabito A; Borzumati V; Dattola V; Gattuso C; Moschella A; Quattrone D; Curmaci F; Franzutti C; Scappatura G; Rao CM; Loddo V; Pontari A; Pellicano' M; Surace R; Sanguedolce C; Naso V; Ferreri A; Irrera G; Console G; Moscato T; Loteta B; Canale FA; Trimarchi A; Monteleone R; Al Sayyad S; Cirrone F; Bruno B
Expert Opin Biol Ther; 2022 Mar; 22(3):407-421. PubMed ID: 34463175
[TBL] [Abstract][Full Text] [Related]
28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials.
Raymakers AJN; Regier DA; Peacock SJ; Freeman CL
J Cancer Policy; 2021 Dec; 30():100304. PubMed ID: 35559800
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
31. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
32. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
33. Using Patient-Reported Outcome Measures (PROMs) to promote quality of care and safety in the management of patients with Advanced Chronic Kidney disease (PRO-trACK project): a mixed-methods project protocol.
Aiyegbusi OL; Kyte D; Cockwell P; Marshall T; Dutton M; Slade A; Marklew N; Price G; Verdi R; Waters J; Sharpe K; Calvert M
BMJ Open; 2017 Jun; 7(6):e016687. PubMed ID: 28667225
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma.
Seyedin R; Snider JT; Rajagopalan K; Wade SW; Gergis U
Future Oncol; 2023 Jul; 19(22):1535-1547. PubMed ID: 37578377
[TBL] [Abstract][Full Text] [Related]
35. Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference study.
Philipps L; Foster S; Gardiner D; Gath J; Gillman A; Haviland J; Hill E; King D; Manning G; Stiles M; Hall E; Lewis R
BMJ Open; 2023 Sep; 13(9):e073817. PubMed ID: 37734892
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
37. A real-time electronic symptom monitoring system for patients after discharge following surgery: a pilot study in cancer-related surgery.
Richards HS; Blazeby JM; Portal A; Harding R; Reed T; Lander T; Chalmers KA; Carter R; Singhal R; Absolom K; Velikova G; Avery KNL
BMC Cancer; 2020 Jun; 20(1):543. PubMed ID: 32522163
[TBL] [Abstract][Full Text] [Related]
38. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
39. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
